BASO~ACS President
Specialty Interest: Breast
Professor of Surgical Sciences and Breast
Cancer
Nuffield Department of Surgical Sciences
University of Oxford
Professor Michael Douek has been a member of BASO
since 1998 and served on BASO Council as an Ordinary Member since
2011 and as Meetings Secretary from 2015 to 2020. He was appointed
BASO Honorary Secretary in 2020, was elected as BASO Vice-President
in 2021 and succeeded as BASO President on 7th November 2023 for 2
years.
Professor Douek graduated from the University of
Dundee (Scotland) and trained in surgery in London, Oxford and
Cambridge. He obtained his MD from the University of London in
2000. In 2003, he was awarded a prestigious Health Foundation
Clinician Scientist grant by the UK Academy of Medical Sciences,
funding his joint Senior Lecturer and Consultant post at University
College London, joining the only surgical oncology firm in the UK
under the leadership of Professor Irving Taylor (Past-President of
BASO, ESSO and Previous Editor-in-Chief of EJSO). In 2009, he moved
to King's College London / Guy's & St Thomas' Hospitals where
he was Professor of Surgical Oncology. In 2019 he was
appointed as Rosetrees RCS Director of the Surgical Intervention
Trials Unit and Professor of Surgical Sciences & Breast Cancer
at the Nuffield Department of Surgical Sciences, University of
Oxford.
Professor Douek is a breast cancer surgeon and
surgical oncologist with a special interest in novel techniques for
cancer surgery, breast reconstruction and clinical trials. He was
awarded a Hunterian Professorship by the Royal College of Surgeons
of England in 2015 and became Research Professor at the Royal
College of Surgeons of England in 2019. He is passionate about
clinical research and was chief investigator of numerous clinical
trials including trials evaluating a magnetic technique for
sentinel node biopsy, which he pioneered. Is is currently a chief
investigator of the EndoNET Trial (NIHR / HTA funded national
trial) a randomised controlled trial evaluating the effectiveness
of neoadjuvant endocrine treatment in post-menopausal women with
breast cancer.